Volastra Therapeutics Inc. has entered into partnerships with Microsoft Corp., Function Oncology Inc. and Tailor Bio Ltd. with the goal of expanding the potential use of its KIF18A inhibitors.
Volastra Therapeutics Inc. has announced new data from its lead program, a KIF18A inhibitor, validating its therapeutic approach of synthetic lethality to induce tumor cell death.
Volastra Therapeutics Inc., dedicated to taking aim at chromosomal instability (CIN) to design cancer drugs by way of its CINtech platform,, scored a potential $1 billion-plus agreement with Bristol Myers Squibb Co. (BMS) to find synthetic lethal targets as drug candidates.
The three founders of newly launched Volastra Therapeutics Inc. had plenty in common when they decided to create the company. Their offices happened to be a half block apart on 69th Street in midtown Manhattan. Their interests in oncology were similar but each approached the disease from different angles.
